Jane Street Group LLC Makes New Investment in Delcath Systems, Inc. (NASDAQ:DCTH)

Jane Street Group LLC purchased a new stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 12,208 shares of the company’s stock, valued at approximately $110,000.

A number of other hedge funds have also recently modified their holdings of the company. Point72 Asia Singapore Pte. Ltd. acquired a new position in Delcath Systems in the third quarter valued at about $102,000. Riverwater Partners LLC purchased a new stake in shares of Delcath Systems in the 3rd quarter valued at approximately $161,000. Cubist Systematic Strategies LLC acquired a new position in shares of Delcath Systems in the 2nd quarter worth approximately $370,000. Renaissance Technologies LLC purchased a new position in shares of Delcath Systems during the 2nd quarter worth approximately $694,000. Finally, State Street Corp increased its holdings in Delcath Systems by 12.4% in the 3rd quarter. State Street Corp now owns 85,457 shares of the company’s stock valued at $772,000 after purchasing an additional 9,400 shares during the last quarter. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Trading Down 0.8 %

Delcath Systems stock opened at $12.69 on Wednesday. The firm has a market capitalization of $405.75 million, a P/E ratio of -9.40 and a beta of 0.87. Delcath Systems, Inc. has a twelve month low of $3.70 and a twelve month high of $13.30. The stock’s fifty day simple moving average is $11.33 and its 200-day simple moving average is $9.83.

Analysts Set New Price Targets

A number of research firms have commented on DCTH. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a research note on Tuesday. Canaccord Genuity Group reissued a “buy” rating and set a $21.00 target price on shares of Delcath Systems in a research note on Friday, October 18th. StockNews.com raised Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. Finally, Stephens reiterated a “buy” rating on shares of Delcath Systems in a research note on Friday, October 18th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $21.50.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.